Rationale for combined therapies in severe-to-critical COVID-19 patients
Por favor, use este identificador para citar o enlazar este ítem:
http://hdl.handle.net/10045/137107
Título: | Rationale for combined therapies in severe-to-critical COVID-19 patients |
---|---|
Autor/es: | Gonzaga, Aitor | Andreu, Etelvina | Hernández-Blasco, Luis M. | Meseguer, Rut | Al-Akioui-Sanz, Karima | Soria-Juan, Bárbara | Sanjuan-Gimenez, Jose Carlos | Ferreras, Cristina | Tejedo, Juan R. | López-Lluch, Guillermo | Goterris, Rosa | Maciá Soler, Loreto | Sempere Ortells, José Miguel | Hmadcha, Abdelkrim | Borobia, Alberto | Vicario, Jose L. | Bonora, Ana | Aguilar-Gallardo, Cristobal | Poveda, Jose L. | Arbona, Cristina | Alenda, Cristina | Tarín, Fabian | Marco, Francisco M. | Merino, Esperanza | Jaime, Francisco | Ferreres, José | Figueira, Juan Carlos | Cañada-Illana, Carlos | Querol, Sergio | Guerreiro, Manuel | Eguizabal, Cristina | Martín-Quirós, Alejandro | Robles-Marhuenda, Ángel | Pérez-Martínez, Antonio | Solano, Carlos | Soria, Bernat |
Grupo/s de investigación o GITE: | Gestión de Servicios de Enfermería (GESE) | Grupo de Inmunología, Biología Celular y del Desarrollo |
Centro, Departamento o Servicio: | Universidad de Alicante. Departamento de Enfermería | Universidad de Alicante. Departamento de Biotecnología |
Palabras clave: | COVID-19 | Cytokine storm | Immunomodulation | Mesenchymal stromal cells | SARS-CoV-2 | Advanced therapies |
Fecha de publicación: | 11-sep-2023 |
Editor: | Frontiers Media |
Cita bibliográfica: | Gonzaga A, Andreu E, Hernández-Blasco LM, Meseguer R, Al-Akioui-Sanz K, Soria-Juan B, Sanjuan-Gimenez JC, Ferreras C, Tejedo JR, Lopez-Lluch G, Goterris R, Maciá L, Sempere-Ortells JM, Hmadcha A, Borobia A, Vicario JL, Bonora A, Aguilar-Gallardo C, Poveda JL, Arbona C, Alenda C, Tarín F, Marco FM, Merino E, Jaime F, Ferreres J, Figueira JC, Cañada-Illana C, Querol S, Guerreiro M, Eguizabal C, Martín-Quirós A, Robles-Marhuenda Á, Pérez-Martínez A, Solano C and Soria B (2023) Rationale for combined therapies in severe-to-critical COVID-19 patients. Front. Immunol. 14:1232472. doi: 10.3389/fimmu.2023.1232472 |
Resumen: | An unprecedented global social and economic impact as well as a significant number of fatalities have been brought on by the coronavirus disease 2019 (COVID-19), produced by the severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2). Acute SARS-CoV-2 infection can, in certain situations, cause immunological abnormalities, leading to an anomalous innate and adaptive immune response. While most patients only experience mild symptoms and recover without the need for mechanical ventilation, a substantial percentage of those who are affected develop severe respiratory illness, which can be fatal. The absence of effective therapies when disease progresses to a very severe condition coupled with the incomplete understanding of COVID-19’s pathogenesis triggers the need to develop innovative therapeutic approaches for patients at high risk of mortality. As a result, we investigate the potential contribution of promising combinatorial cell therapy to prevent death in critical patients. |
Patrocinador/es: | This research was funded by the financial support to BS from: Institute of Health Carlos III (Co-funded by Fondos FEDER), Project ICI21/00016 and Agencia Valenciana de Innovacion Projects AVI-GVA COVID-19-68 and GVA-COVI19/2021/047 and Project JDRF 2-SRA-2019-837. |
URI: | http://hdl.handle.net/10045/137107 |
ISSN: | 1664-3224 |
DOI: | 10.3389/fimmu.2023.1232472 |
Idioma: | eng |
Tipo: | info:eu-repo/semantics/article |
Derechos: | © 2023 Gonzaga, Andreu, Hernández-Blasco, Meseguer, Al-Akioui-Sanz, Soria-Juan, Sanjuan-Gimenez, Ferreras, Tejedo, Lopez-Lluch, Goterris, Maciá, Sempere-Ortells, Hmadcha, Borobia, Vicario, Bonora, Aguilar-Gallardo, Poveda, Arbona, Alenda, Tarín, Marco, Merino, Jaime, Ferreres, Figueira, Cañada-Illana, Querol, Guerreiro, Eguizabal, Martín-Quirós, Robles-Marhuenda, Pérez-Martínez, Solano and Soria. This is an open-access article distributed under the terms of the Creative Commons Attribution License (CC BY). The use, distribution or reproduction in other forums is permitted, provided the original author(s) and the copyright owner(s) are credited and that the original publication in this journal is cited, in accordance with accepted academic practice. No use, distribution or reproduction is permitted which does not comply with these terms. |
Revisión científica: | si |
Versión del editor: | https://doi.org/10.3389/fimmu.2023.1232472 |
Aparece en las colecciones: | INV - Grupo de Inmunología - Artículos de Revistas INV - GESE - Artículos de Revistas |
Archivos en este ítem:
Archivo | Descripción | Tamaño | Formato | |
---|---|---|---|---|
Gonzaga_etal_2023_FrontImmunol.pdf | 2,19 MB | Adobe PDF | Abrir Vista previa | |
Este ítem está licenciado bajo Licencia Creative Commons